AdjuCor receives further funding for its innovative heart assist device which avoids blood-contact and supports patients with heart failure.

MUNICH, Germany – August 26th, 2019: After reaching a key milestone towards clinical application with a successful 60 day in-vivo study, AdjuCor announces the closure of a new financing round with Hirschvogel Vermögensverwaltung GmbH, a Bavarian Investor who intends to further expand its activity into the medical device arena.

Hirschvogel Vermögensverwaltung GmbH announces its new investment into the innovative MedTech Company AdjuCor to further develop their unique non-blood contacting heart assist device. “This is one of the most outstanding technologies I have seen in the last years”, commented Dr. Marc Hirschvogel, CEO of Hirschvogel Vermögensverwaltung GmbH, and continued: “Having expertise in this field, due to my background in computational mechanics and engineering in cardiovascular medicine, I am convinced that this non-blood-contacting device will set a key milestone in treatment of advanced heart failure and gives engineers room for more exciting products in the future. For us, this investment will be a strategic step towards further activities in the medical device arena.”

Prof. Stephan Schueler, Director of Cardiac Transplant and Assist Device Therapy at Freeman Hospital in Newcastle upon Tyne, UK pointed out that many obstacles in current assist device therapy are directly linked to foreign surfaces contacting the blood stream. “If we would be able to enhance blood pressure and circulation without having to place devices into the heart and major vessels, we could definitively improve the care and the quality of life of our patients. Because the AdjuCor device avoids the blood contact, it has the potential to significantly change the way heart failure patients will be treated. I am looking forward to participate in the clinical study, in the near future.”

AdjuCor’s Innovative Extravascular, Biventricular Cardiac Support Technology
What sets AdjuCor’ patented technology apart from the other LVADs currently available on the market, is its unique non-blood-contacting solution, its ability to support both ventricles, and its innovative patient-specific design. It is implanted by a heart team (cardiologist and cardiac surgeon) around the heart within a few minutes on the beating heart without sutures. It completely avoids blood contact and thereby any blood-related complications including strokes and bleeding – an invaluable advantage that cannot be over-stated. The energy transferred to the heart may be adjusted to each patient’s need. It thereby dramatically enhances the care of patients with heart failure and improves their quality of life.

AdjuCor was founded as GmbH in 2012 by the Cardiothoracic Surgeon Stephen Wildhirt and is funded by private investors, the European Union, as well as German and Bavarian entities. The company employs over thirty experts in all fields required and has received over 13 million euros of financing.




Biventricular assistance for patients with advanced heart failure

The non-blood-contacting, biventricular cardiac support device of AdjuCor is a medical device currently under preclinical investigation.